BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in <i>BRAF</i>-Mutated Metastatic Colorectal Cancer—A Case Series Study <i>Target Therapy of</i> BRAF-<i>Mutated mCRC</i>

BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in <i>BRAF</i>-Mutated Metastatic Colorectal Cancer—A Case Series Study <i>Target Therapy of</i> BRAF-<i>Mutated mCRC</i>

<i>Background</i><i>and objectives</i>: Patients with <i>BRAF</i>-mutated metastatic colorectal cancer have considerably poorer responses to conventional systemic treatment. The real-world effects of triplet therapy with BRAF, mitogen-activated protein kinase kina...

Full description

Bibliographic Details
Main Authors: Jen-Hao Yeh, Hsiang-Lin Tsai, Yen-Cheng Chen, Ching-Chun Li, Ching-Wen Huang, Tsung-Kun Chang, Wei-Chih Su, Po-Jung Chen, Yu-Peng Liu, Jaw-Yuan Wang
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Medicina
Subjects:
metastatic colorectal cancer
<i>BRAF</i> mutation
triple target therapy
Online Access:https://www.mdpi.com/1648-9144/57/12/1339

Internet

https://www.mdpi.com/1648-9144/57/12/1339

Similar Items